Literature DB >> 29248454

Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice.

Liyuan Li1, Maoxiang Qian1, I-Hsuan Chen2, David Finkelstein3, Arzu Onar-Thomas4, Melissa Johnson5, Christopher Calabrese5, Armita Bahrami6, Dolores H López-Terrada7, Jun J Yang1, W Andy Tao2, Liqin Zhu8.   

Abstract

Past studies have identified hepatic tumors with mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) characteristics that have a more aggressive behavior and a poorer prognosis than classic HCC. Whether this pathologic heterogeneity is due to a cell of origin of bipotent liver progenitors or the plasticity of cellular constituents comprising these tumors remains debated. In this study, we investigated the potential acquisition of CC-like traits during advanced development of HCC in mice. Primary and rare high-grade HCC developed in a genetic mouse model. A mouse model of highly efficient HCC invasion and metastasis by orthotopic transplantation of liver cancer organoids propagated from primary tumors in the genetic model was further developed. Invasive/metastatic tumors developed in both models closely recapitulated advanced human HCC and displayed a striking acquisition of CC-related pathologic and molecular features, which was absent in the primary HCC tumors. Our study directly demonstrates the pathologic evolution of HCC during advanced tumor development, providing the first evidence that tumors with mixed HCC and CC features, or at least a subset of these tumors, represent a more advanced developmental stage of HCC. Finally, liver cancer organoid-generated high-grade tumors exhibited significantly increased extracellular vesicle secretion, suggesting that identifying tumor-specific extracellular vesicle proteins in plasma may be a promising tool for liver cancer detection.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29248454      PMCID: PMC5840495          DOI: 10.1016/j.ajpath.2017.11.013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  83 in total

1.  Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.

Authors:  Dominique Cazals-Hatem; Sandra Rebouissou; Paulette Bioulac-Sage; Olivier Bluteau; Hélène Blanché; Dominique Franco; Geneviève Monges; Jacques Belghiti; Antonio Sa Cunha; Pierre Laurent-Puig; Claude Degott; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2004-08       Impact factor: 25.083

Review 2.  Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Authors:  K Breuhahn; T Longerich; P Schirmacher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 3.  Exosomes: proteomic insights and diagnostic potential.

Authors:  Richard J Simpson; Justin We Lim; Robert L Moritz; Suresh Mathivanan
Journal:  Expert Rev Proteomics       Date:  2009-06       Impact factor: 3.940

4.  CD13 is a therapeutic target in human liver cancer stem cells.

Authors:  Naotsugu Haraguchi; Hideshi Ishii; Koshi Mimori; Fumiaki Tanaka; Masahisa Ohkuma; Ho Min Kim; Hirofumi Akita; Daisuke Takiuchi; Hisanori Hatano; Hiroaki Nagano; Graham F Barnard; Yuichiro Doki; Masaki Mori
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

5.  Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.

Authors:  Augusto Villanueva; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2012-02-21       Impact factor: 12.531

Review 6.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

7.  Pathview: an R/Bioconductor package for pathway-based data integration and visualization.

Authors:  Weijun Luo; Cory Brouwer
Journal:  Bioinformatics       Date:  2013-06-04       Impact factor: 6.937

8.  WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.

Authors:  Luke Boulter; Rachel V Guest; Timothy J Kendall; David H Wilson; Davina Wojtacha; Andrew J Robson; Rachel A Ridgway; Kay Samuel; Nico Van Rooijen; Simon T Barry; Stephen J Wigmore; Owen J Sansom; Stuart J Forbes
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

9.  The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection.

Authors:  Chao-Wei Lee; Wen-Ling Kuo; Ming-Chin Yu; Tse-Ching Chen; Chi-Neu Tsai; Wei-Chen Lee; Miin-Fu Chen
Journal:  World J Surg Oncol       Date:  2013-06-12       Impact factor: 2.754

10.  Human hepatic stem cells from fetal and postnatal donors.

Authors:  Eva Schmelzer; Lili Zhang; Andrew Bruce; Eliane Wauthier; John Ludlow; Hsin-lei Yao; Nicholas Moss; Alaa Melhem; Randall McClelland; William Turner; Michael Kulik; Sonya Sherwood; Tommi Tallheden; Nancy Cheng; Mark E Furth; Lola M Reid
Journal:  J Exp Med       Date:  2007-07-30       Impact factor: 14.307

View more
  3 in total

Review 1.  Organoids for the Study of Liver Cancer.

Authors:  Haichuan Wang; Diego F Calvisi; Xin Chen
Journal:  Semin Liver Dis       Date:  2021-02-09       Impact factor: 6.115

Review 2.  Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.

Authors:  Joon Hyuk Choi; Jae Y Ro
Journal:  Biomedicines       Date:  2022-07-29

Review 3.  Organoid models of gastrointestinal cancers in basic and translational research.

Authors:  Harry Cheuk Hay Lau; Onno Kranenburg; Haipeng Xiao; Jun Yu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-25       Impact factor: 46.802

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.